cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 Novo Nordisk's shows promising weight loss in REDEFINE-1 sub-analysis, unveiled at EASD Cagrilintide–semaglutide (CagriSema) versus semaglutide or
Description
doi: 10.1152/ajpgi.1999.276.4.G951
00125-7/asset/25d10da2-038c-4d13-b485-c9856810af68/main.assets/gr3_lrg.jpg)
Regular monitoring: Ongoing bloodwork to catch any concerning trends
Alternate between multiple sites to prevent lipohypertrophy (fatty lumps under skin), reduce scar tissue formation, and maintain consistent absorption
10.1002/hep.20969 [DOI] [PubMed] [Google Scholar] Fujiyoshi M., Ozaki M
